Dublin, May 12, 2020 (GLOBE NEWSWIRE) -- The "Essential Thrombocythemia (ET) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Essential Thrombocythemia (ET), historical and forecasted epidemiology as well as the Essential Thrombocythemia (ET) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Essential Thrombocythemia (ET) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Essential Thrombocythemia (ET) market size from 2017 to 2030. The Report also covers current Essential Thrombocythemia (ET) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

According to the MPN Research Foundation, Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increased number of platelets in the blood. The overproduction (megakaryocytic hyperplasia) of platelet-forming cells, called megakaryocytes, in the marrow results in the release of too many platelets into the blood.

The term essential indicates that the increase in platelets is an inherent problem of the blood cell production in the bone marrow and Thrombocythemia refers to an excess of platelets in the blood. Also, the increased platelet count may result in the blockage in blood vessels (thrombus), splenomegaly, and hemorrhagic episodes. Most cases of ET are not inherited, and it arises from gene mutations that occur in early blood-forming cells after conception. However, in very rare cases, ET is inherited in an autosomal dominant pattern and known as familial Essential Thrombocythemia.

The typical pattern of ET onset is bimodal, with one peak occurring during young adulthood in females and the other peak occurring between the ages of 50-70 years in both males and females. The incidence of ET is around 1.5-2 times higher in females as compared to males.

Essential Thrombocythemia (ET) Diagnosis

The diagnosis of ET is based on the complete blood count, blood smear examination, genetic and bone marrow testing. Some of the patients may be asymptomatic and found to have an increased platelets count. By carefully examining the results of the above-mentioned diagnostic tests and by reviewing the patient's clinical history and symptoms, a physician can diagnose ET.

Scope of the Report

• The report covers the descriptive overview of Essential Thrombocythemia (ET), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Essential Thrombocythemia (ET) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Essential Thrombocythemia (ET) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Essential Thrombocythemia (ET) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Essential Thrombocythemia (ET) market.

Report Highlights

• In the coming years, Essential Thrombocythemia (ET) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Essential Thrombocythemia (ET) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Essential Thrombocythemia (ET). Launch of emerging therapies will significantly impact the Essential Thrombocythemia (ET) market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Topics Covered:

1. Key Insights

2. Executive Summary of Essential Thrombocythemia (ET)

3. Essential Thrombocythemia (ET): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of ET in 2017
3.2. Total Market Share (%) Distribution of ET in 2030

4. Disease Background and Overview: Essential Thrombocythemia (ET)
4.1. Introduction
4.2. Symptoms
4.3. Causes
4.4. Risk Factors
4.5. Pathogenesis
4.6. Diagnosis of ET
4.6.1. 2016 World Health Organization Diagnostic Criteria for Essential Thrombocythemia
4.6.2. Diagnostic criteria of essential thrombocythemia by the British Committee for Standards in Haematology
4.6.3. International Prognostic Score for Thrombosis in Essential Thrombocythemia
4.6.4. Diagnostic algorithm

5. Case Reports
5.1. A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge
5.2. Case Report: Headache in a Postpartum Patient with Essential Thrombocytosis
5.3. Essential Thrombocythemia in a young man treated for myocardial infarction
5.4. Next-generation sequencing redefines a triple-negative Essential Thrombocythemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots
5.5. JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Essential Thrombocythemia (ET) in the United States
7.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the United States
7.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in the United States
7.5. Age-specific Diagnosed Prevalence of ET in the United States
7.6. Prevalence of ET Cases Based on Risk in the United States
7.7. Gene Mutation specific Prevalence of ET in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Germany
8.1.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany
8.1.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Germany
8.1.5. Age-specific Diagnosed Prevalence of ET in Germany
8.1.6. Prevalence of ET Cases Based on Risk in Germany
8.1.7. Gene Mutation specific Prevalence of ET in Germany
8.2. France Epidemiology
8.3. Italy Epidemiology
8.4. Spain Epidemiology
8.5. United Kingdom Epidemiology

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Prevalent Population of Essential Thrombocythemia (ET) Japan
9.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan
9.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Japan
9.5. Age-specific Diagnosed Prevalence of ET in Japan
9.6. Prevalence of ET Cases Based on Risk in Japan
9.7. Gene Mutation specific Prevalence of ET in Japan

10. Current Treatment and Medical Practices
10.1. Risk categories of patients with ET
10.2. Treatment of Essential Thrombocythemia (ET)
10.3. Treatment Algorithm
10.4. Treatment Guidelines
10.4.1. National Comprehensive Cancer Network Guidelines
10.4.2. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
10.4.3. UCLP Myeloproliferative Neoplasms Group: Essential Thrombocythaemia Guideline
10.4.4. The Japanese Society of Hematology guidelines for the treatment of Essential Thrombocythaemia

11. Unmet Needs

12. Marketed Drugs
12.1. Agrylin/Xagrid: Shire
12.1.1. Product Description
12.1.2. Regulatory Milestones
12.1.3. Safety and Efficacy
12.1.4. Product Profile
12.2. Thromboreductin: AOP Orphan Pharmaceuticals
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Safety and Efficacy
12.2.4. Product Profile

13. Emerging Therapies
13.1. Ropeginterferon alfa-2b (P1101): PharmaEssentia
13.2. Jakavi (ruxolitinib): Novartis
13.3. Bomedemstat (IMG-7289): Imago BioSciences
13.4. Gandotinib (LY2784544): Eli Lilly and Company
13.5. Imetelstat: Geron Corporation
13.6. Givinostat (ITF2357): Italfarmaco
13.7. Anagrelide Controlled Release/GALE-401: Galena Biopharma

14. Essential Thrombocythemia (ET): 7MM Market Analysis
14.1. Key Findings
14.2. Market Size of Essential Thrombocythemia (ET) in the 7MM
14.3. Market Size of Essential Thrombocythemia (ET) by Therapies in the 7MM

15. United States
15.1. United States: Market Outlook
15.2. United States Market Size
15.2.1. Total Market size of Essential Thrombocythemia (ET) in the US
15.2.2. Market Size of Essential Thrombocythemia (ET) by Therapies in the US

16. EU-5 countries
16.1. EU-5 Market Outlook
16.2. Germany Market Size
16.3. France Market Size
16.4. Italy Market Size
16.5. Spain Market Size
16.6. United Kingdom Market Size

17. Japan
17.1. Market Outlook
17.2. Japan Market Size
17.2.1. Total Market size of Essential Thrombocythemia (ET) in Japan
17.2.2. Market Size of Essential Thrombocythemia (ET) by therapies in Japan

18. Market Drivers

19. Market Barriers

20. Reimbursement and Market Access

21. SWOT Analysis

22. KOL Views

23. Appendix

24. Bibliography
24.1. Report Methodology

25. The Publisher's Capabilities

26. Disclaimer

27. About the Publisher

Companies Mentioned

• Shire
• AOP Orphan Pharmaceuticals
• PharmaEssentia
• Novartis
• Imago BioSciences

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/v2hhzp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900